Art

J-GLOBAL ID：201802256870917928   Reference number：18A1141204

Emerging therapies for acute myeloid leukemia

急性骨髄性白血病の新たな治療法【JST・京大機械翻訳】

Author (3)： Saygin Caner (Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA) ,  Carraway Hetty E. (Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA) ,  Carraway Hetty E. (Department of Hematology and Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA)
Material： Journal of Hematology & Oncology (Web)
Volume： 10  Issue： 1  Page： 93  Publication year： 2017 
JST Material Number： U7517A  ISSN： 1756-8722  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Acute myeloid leukemia (AML) i...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1141204&from=J-GLOBAL&jstjournalNo=U7517A") }}

Thesaurus term： *acute myeloid leukemia ,  receptor tyrosine kinase ,  epigenetics ,  antibody ,  new drug ,  cytotoxicity ,  drug therapy ,  heterogeneity ,  cell cycle ,  aminopeptidase ,  recurrence ,  B cell lymphoma ,  histone deacetylase
Semi thesaurus term： ブロモドメイン ,  阻害剤 , 【Automatic Indexing@JST】

Author keywords (14)： AML ,  CPX-351 ,  Vosaroxin ,  Guadecitabine ,  IDH ,  HDAC ,  BET ,  DOT1L ,  LSD1 ,  FLT3 ,  Vadastuximab ,  Volasertib ,  Venetoclax ,  Tosedostat

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Reference (88)：

• N Eng J Med; Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia; 368; 22; 2013; 2059-74; 10.1056/NEJMoa1301689; CR1;
• N Eng J Med; Genomic classification and prognosis in acute myeloid leukemia; EGM Papaemmanuil, L Bullinger, VI Gaidzik, P Paschka, ND Roberts, NE Potter, M Heuser, F Thol, N Bolli, G Gundem, P Loo, I Martincorena, P Ganly, L Mudie, S McLaren, S O’Meara, K Raine, DR Jones, JW Teague, AP Butler, MF Greaves, A Ganser, K Döhner, RF Schlenk, H Döhner, PJ Campbell; 374; 23; 2016; 2209-21; 10.1056/NEJMoa1516192; CR2;
• Blood; Emerging therapeutic drugs for AML; EM Stein, MS Tallman; 127; 1; 2016; 71-8; 10.1182/blood-2015-07-604538; CR3;
• Podoltsev NA SM, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2016. In press.
• J Hematol Oncol; Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications; LBS Pleyer, R Stauder, M Girschikofsky, H Sill, K Schlick, J Thaler, B Halter, S Machherndl-Spandl, A Zebisch, A Pichler, M Pfeilstöcker, E-M Autzinger, A Lang, K Geissler, D Voskova, D Geissler, WR Sperr, S Hojas, IM Rogulj, J Andel, R Greil; 9; 1; 2016; 39; 10.1186/s13045-016-0263-4; CR5;

Terms in the title (2)： 急性骨髄性白血病 ,  治療法